###begin article-title 0
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
The Hellenic type of nondeletional hereditary persistence of fetal hemoglobin results from a novel mutation (g.-109G>T) in the HBG2 gene promoter
###end article-title 0
###begin p 1
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 237 241 237 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 398 402 398 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 658 662 654 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 754 758 750 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 814 817 810 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 989 993 982 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1167 1173 1160 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2/1</italic>
###xml 1240 1244 1233 1237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1299 1303 1292 1296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 208 213 <span type="species:ncbi:9606">human</span>
Nondeletional hereditary persistence of fetal hemoglobin (nd-HPFH), a rare hereditary condition resulting in elevated levels of fetal hemoglobin (Hb F) in adults, is associated with promoter mutations in the human fetal globin (HBG1 and HBG2) genes. In this paper, we report a novel type of nd-HPFH due to a HBG2 gene promoter mutation (HBG2:g.-109G>T). This mutation, located at the 3' end of the HBG2 distal CCAAT box, was initially identified in an adult female subject of Central Greek origin and results in elevated Hb F levels (4.1%) and significantly increased Ggamma-globin chain production (79.2%). Family studies and DNA analysis revealed that the HBG2:g.-109G>T mutation is also found in the family members in compound heterozygosity with the HBG2:g.-158C>T single nucleotide polymorphism or the silent HBB:g.-101C>T beta-thalassemia mutation, resulting in the latter case in significantly elevated Hb F levels (14.3%). Electrophoretic mobility shift analysis revealed that the HBG2:g.-109G>T mutation abolishes a transcription factor binding site, consistent with previous observations using DNA footprinting analysis, suggesting that guanine at position HBG2/1:g.-109 is critical for NF-E3 binding. These data suggest that the HBG2:g-109G>T mutation has a functional role in increasing HBG2 transcription and is responsible for the HPFH phenotype observed in our index cases.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 300 301 300 301 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 307 308 307 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 655 658 651 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBD</italic>
###xml 686 687 682 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 696 697 692 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
Hereditary persistence of fetal hemoglobin (HPFH) is a genetic condition characterized by persistent elevated levels of fetal hemoglobin (Hb F) in the adult erythroid stage [1]. HPFH heterozygotes have a normal clinical phenotype and hematological indices, except for the lower levels of hemoglobin A2 (Hb A2) that constitutes the hallmark of HPFH. The reason for that is the increased frequency of interactions between the locus control region (LCR) and the mutated gamma-globin gene promoter compared to the normal situation. Subsequently, this shifts the transcriptional balance in favor to the otherwise silent, fetal globin genes, resulting in lower HBD gene transcription and Hb A2 levels [2].
###end p 4
###begin p 5
###xml 253 254 253 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 592 593 588 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
The various forms of HPFH are distinguished into two main categories, namely, deletional and nondeletional HPFH (nd-HPFH), due to large deletions 3' to the fetal globin genes or nucleotide substitutions in the fetal globin gene promoters, respectively [3]. The current explanation for the functional role of the latter HPFH category is the destabilization of a yet unknown silencing protein complex that permits LCR-gene interactions and recruitment of the basal transcriptional machinery to the mutated gamma-globin gene promoter, leading to reactivation of fetal globin gene transcription [4].
###end p 5
###begin p 6
###xml 131 134 123 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 156 157 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 206 210 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 222 223 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 290 291 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 273 288 <span type="species:ncbi:10090">transgenic mice</span>
###xml 713 718 <span type="species:ncbi:9606">human</span>
To date, there are few gamma-globin promoter mutations, leading to nd-HPFH clustered on or in close proximity to gamma-globin gene cis-regulatory elements [5]. The most important nd-HPFH is the Greek type (HBG1:g.-117G>A [6]), whose functional role is also demonstrated in transgenic mice [7]. This mutation is located at the 5' end of the distal gamma-globin gene CCAAT box where important erythroid-specific transcription factors bind. Other mutations cluster approximately 200 bp upstream to the gamma-globin genes transcription initiation site where a GC-rich region is located. Although clinically silent, the mutations leading to nd-HPFH provide valuable insights into the transcriptional regulation of the human fetal globin genes, which in turn can enable design of novel strategies for beta-thalassemia therapeutics.
###end p 6
###begin p 7
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
In this communication, we report the Hellenic type of nd-HPFH due to a novel G>T transversion in the HBG2 gene promoter, located at the 3' end of the distal HBG2 CCAAT box.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Case selection
###end title 9
###begin p 10
###xml 213 214 213 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 256 259 256 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 322 323 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 447 453 444 450 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 453 454 450 451 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 576 580 573 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 622 627 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black</italic>
###xml 637 641 634 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 678 688 675 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">light gray</italic>
###xml 704 707 701 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 766 775 760 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dark gray</italic>
###xml 830 831 824 825 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 453 950 450 936 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="11"><bold>a</bold> Family tree showing the heterozygous and compound heterozygous cases for the Hellenic type of nd-HPFH, bearing the novel <italic>HBG2</italic>:g.-109G&gt;T promoter mutation (depicted in <italic>black</italic>) and the <italic>HBG2</italic>:g.-158C&gt;T polymorphism (depicted in <italic>light gray</italic>) or the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia nonsense mutation (depicted in <italic>dark gray</italic>), along with the corresponding hematological indices. <bold>b</bold> Chromatogram from RP-HPLC from the index case showing the significant increase in the G&#947;/A&#947;-globin chain ratio</p>
###xml 453 950 450 936 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="11"><bold>a</bold> Family tree showing the heterozygous and compound heterozygous cases for the Hellenic type of nd-HPFH, bearing the novel <italic>HBG2</italic>:g.-109G&gt;T promoter mutation (depicted in <italic>black</italic>) and the <italic>HBG2</italic>:g.-158C&gt;T polymorphism (depicted in <italic>light gray</italic>) or the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia nonsense mutation (depicted in <italic>dark gray</italic>), along with the corresponding hematological indices. <bold>b</bold> Chromatogram from RP-HPLC from the index case showing the significant increase in the G&#947;/A&#947;-globin chain ratio</p></caption>
###xml 950 950 936 936 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="277_2008_643_Fig1_HTML" id="MO1"/>
###xml 447 950 444 936 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="11"><bold>a</bold> Family tree showing the heterozygous and compound heterozygous cases for the Hellenic type of nd-HPFH, bearing the novel <italic>HBG2</italic>:g.-109G&gt;T promoter mutation (depicted in <italic>black</italic>) and the <italic>HBG2</italic>:g.-158C&gt;T polymorphism (depicted in <italic>light gray</italic>) or the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia nonsense mutation (depicted in <italic>dark gray</italic>), along with the corresponding hematological indices. <bold>b</bold> Chromatogram from RP-HPLC from the index case showing the significant increase in the G&#947;/A&#947;-globin chain ratio</p></caption><graphic position="anchor" xlink:href="277_2008_643_Fig1_HTML" id="MO1"/></fig>
###xml 950 957 936 943 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1002 1003 988 989 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1066 1070 1052 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1105 1108 1091 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 1165 1166 1148 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1203 1206 1186 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 957 1296 943 1276 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="12">Comparison of the hematological indices, Hb A<sub>2</sub> and Hb F levels among the compound heterozygous for the novel <italic>HBG2</italic>:g.-109G&gt;T mutation and the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia mutation (I-3; see also Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a), and heterozygotes for the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia mutation (note the markedly increased Hb F levels in case I-3)</p>
###xml 957 1296 943 1276 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="12">Comparison of the hematological indices, Hb A<sub>2</sub> and Hb F levels among the compound heterozygous for the novel <italic>HBG2</italic>:g.-109G&gt;T mutation and the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia mutation (I-3; see also Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a), and heterozygotes for the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia mutation (note the markedly increased Hb F levels in case I-3)</p></caption>
###xml 1296 1317 1276 1297 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="3">Hematological indices</th>
###xml 1317 1320 1297 1300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 1317 1330 1297 1310 <th xmlns:xlink="http://www.w3.org/1999/xlink" colspan="3"><italic>HBB</italic>:g.-101C&gt;T</th>
###xml 1296 1330 1276 1310 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="3">Hematological indices</th><th colspan="3"><italic>HBB</italic>:g.-101C&gt;T</th></tr>
###xml 1330 1334 1310 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1330 1350 1310 1330 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2"><italic>HBG2</italic>:g.-109G&gt;T (I-3)</th>
###xml 1350 1359 1330 1339 <th xmlns:xlink="http://www.w3.org/1999/xlink">Wild-type</th>
###xml 1359 1368 1339 1348 <th xmlns:xlink="http://www.w3.org/1999/xlink">Wild-type</th>
###xml 1330 1368 1310 1348 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2"><italic>HBG2</italic>:g.-109G&gt;T (I-3)</th><th>Wild-type</th><th>Wild-type</th></tr>
###xml 1377 1378 1357 1358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1368 1384 1348 1364 <th xmlns:xlink="http://www.w3.org/1999/xlink">Females (<italic>n</italic>&#8201;=&#8201;18)</th>
###xml 1391 1392 1371 1372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1384 1398 1364 1378 <th xmlns:xlink="http://www.w3.org/1999/xlink">Males (<italic>n</italic>&#8201;=&#8201;13)</th>
###xml 1368 1398 1348 1378 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th>Females (<italic>n</italic>&#8201;=&#8201;18)</th><th>Males (<italic>n</italic>&#8201;=&#8201;13)</th></tr>
###xml 1296 1398 1276 1378 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="3">Hematological indices</th><th colspan="3"><italic>HBB</italic>:g.-101C&gt;T</th></tr><tr><th rowspan="2"><italic>HBG2</italic>:g.-109G&gt;T (I-3)</th><th>Wild-type</th><th>Wild-type</th></tr><tr><th>Females (<italic>n</italic>&#8201;=&#8201;18)</th><th>Males (<italic>n</italic>&#8201;=&#8201;13)</th></tr></thead>
###xml 1398 1413 1378 1393 <td xmlns:xlink="http://www.w3.org/1999/xlink">Age (years)/sex</td>
###xml 1413 1417 1393 1397 <td xmlns:xlink="http://www.w3.org/1999/xlink">78/F</td>
###xml 1417 1423 1397 1403 <td xmlns:xlink="http://www.w3.org/1999/xlink">Adults</td>
###xml 1423 1429 1403 1409 <td xmlns:xlink="http://www.w3.org/1999/xlink">Adults</td>
###xml 1398 1429 1378 1409 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Age (years)/sex</td><td>78/F</td><td>Adults</td><td>Adults</td></tr>
###xml 1429 1438 1409 1418 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hb (g/dL)</td>
###xml 1438 1442 1418 1422 <td xmlns:xlink="http://www.w3.org/1999/xlink">12.1</td>
###xml 1442 1455 1422 1433 <td xmlns:xlink="http://www.w3.org/1999/xlink">12.4&#8201;&#177;&#8201;1.22</td>
###xml 1455 1468 1433 1444 <td xmlns:xlink="http://www.w3.org/1999/xlink">14.5&#8201;&#177;&#8201;0.84</td>
###xml 1429 1468 1409 1444 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hb (g/dL)</td><td>12.1</td><td>12.4&#8201;&#177;&#8201;1.22</td><td>14.5&#8201;&#177;&#8201;0.84</td></tr>
###xml 1468 1475 1444 1451 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hct (%)</td>
###xml 1475 1479 1451 1455 <td xmlns:xlink="http://www.w3.org/1999/xlink">38.5</td>
###xml 1479 1492 1455 1466 <td xmlns:xlink="http://www.w3.org/1999/xlink">37.1&#8201;&#177;&#8201;2.76</td>
###xml 1492 1505 1466 1477 <td xmlns:xlink="http://www.w3.org/1999/xlink">43.1&#8201;&#177;&#8201;2.30</td>
###xml 1468 1505 1444 1477 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hct (%)</td><td>38.5</td><td>37.1&#8201;&#177;&#8201;2.76</td><td>43.1&#8201;&#177;&#8201;2.30</td></tr>
###xml 1513 1514 1485 1486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 1505 1515 1477 1487 <td xmlns:xlink="http://www.w3.org/1999/xlink">RBC (&#215;10<sup>6</sup>)</td>
###xml 1515 1520 1487 1492 <td xmlns:xlink="http://www.w3.org/1999/xlink">4,440</td>
###xml 1520 1533 1492 1503 <td xmlns:xlink="http://www.w3.org/1999/xlink">4,382&#8201;&#177;&#8201;446</td>
###xml 1533 1546 1503 1514 <td xmlns:xlink="http://www.w3.org/1999/xlink">5,144&#8201;&#177;&#8201;265</td>
###xml 1505 1546 1477 1514 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>RBC (&#215;10<sup>6</sup>)</td><td>4,440</td><td>4,382&#8201;&#177;&#8201;446</td><td>5,144&#8201;&#177;&#8201;265</td></tr>
###xml 1546 1554 1514 1522 <td xmlns:xlink="http://www.w3.org/1999/xlink">MCH (pg)</td>
###xml 1554 1558 1522 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink">27.3</td>
###xml 1558 1571 1526 1537 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.4&#8201;&#177;&#8201;1.54</td>
###xml 1571 1584 1537 1548 <td xmlns:xlink="http://www.w3.org/1999/xlink">28.5&#8201;&#177;&#8201;0.88</td>
###xml 1546 1584 1514 1548 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>MCH (pg)</td><td>27.3</td><td>28.4&#8201;&#177;&#8201;1.54</td><td>28.5&#8201;&#177;&#8201;0.88</td></tr>
###xml 1584 1592 1548 1556 <td xmlns:xlink="http://www.w3.org/1999/xlink">MCV (fl)</td>
###xml 1592 1596 1556 1560 <td xmlns:xlink="http://www.w3.org/1999/xlink">86.7</td>
###xml 1596 1609 1560 1571 <td xmlns:xlink="http://www.w3.org/1999/xlink">85.5&#8201;&#177;&#8201;4.03</td>
###xml 1609 1622 1571 1582 <td xmlns:xlink="http://www.w3.org/1999/xlink">84.3&#8201;&#177;&#8201;2.69</td>
###xml 1584 1622 1548 1582 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>MCV (fl)</td><td>86.7</td><td>85.5&#8201;&#177;&#8201;4.03</td><td>84.3&#8201;&#177;&#8201;2.69</td></tr>
###xml 1622 1630 1582 1590 <td xmlns:xlink="http://www.w3.org/1999/xlink">MCHC (%)</td>
###xml 1630 1634 1590 1594 <td xmlns:xlink="http://www.w3.org/1999/xlink">31.4</td>
###xml 1634 1647 1594 1605 <td xmlns:xlink="http://www.w3.org/1999/xlink">32.7&#8201;&#177;&#8201;1.04</td>
###xml 1647 1660 1605 1616 <td xmlns:xlink="http://www.w3.org/1999/xlink">33.9&#8201;&#177;&#8201;0.64</td>
###xml 1622 1660 1582 1616 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>MCHC (%)</td><td>31.4</td><td>32.7&#8201;&#177;&#8201;1.04</td><td>33.9&#8201;&#177;&#8201;0.64</td></tr>
###xml 1664 1665 1620 1621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1660 1669 1616 1625 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hb A<sub>2</sub> (%)</td>
###xml 1669 1672 1625 1628 <td xmlns:xlink="http://www.w3.org/1999/xlink">4.3</td>
###xml 1672 1685 1628 1639 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.79&#8201;&#177;&#8201;0.24</td>
###xml 1685 1698 1639 1650 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.92&#8201;&#177;&#8201;0.37</td>
###xml 1660 1698 1616 1650 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hb A<sub>2</sub> (%)</td><td>4.3</td><td>3.79&#8201;&#177;&#8201;0.24</td><td>3.92&#8201;&#177;&#8201;0.37</td></tr>
###xml 1698 1706 1650 1658 <td xmlns:xlink="http://www.w3.org/1999/xlink">Hb F (%)</td>
###xml 1706 1710 1658 1662 <td xmlns:xlink="http://www.w3.org/1999/xlink">14.3</td>
###xml 1710 1722 1662 1672 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.53&#8201;&#177;&#8201;1.8</td>
###xml 1722 1735 1672 1683 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.60&#8201;&#177;&#8201;1.17</td>
###xml 1698 1735 1650 1683 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Hb F (%)</td><td>14.3</td><td>2.53&#8201;&#177;&#8201;1.8</td><td>1.60&#8201;&#177;&#8201;1.17</td></tr>
###xml 1398 1735 1378 1683 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td>Age (years)/sex</td><td>78/F</td><td>Adults</td><td>Adults</td></tr><tr><td>Hb (g/dL)</td><td>12.1</td><td>12.4&#8201;&#177;&#8201;1.22</td><td>14.5&#8201;&#177;&#8201;0.84</td></tr><tr><td>Hct (%)</td><td>38.5</td><td>37.1&#8201;&#177;&#8201;2.76</td><td>43.1&#8201;&#177;&#8201;2.30</td></tr><tr><td>RBC (&#215;10<sup>6</sup>)</td><td>4,440</td><td>4,382&#8201;&#177;&#8201;446</td><td>5,144&#8201;&#177;&#8201;265</td></tr><tr><td>MCH (pg)</td><td>27.3</td><td>28.4&#8201;&#177;&#8201;1.54</td><td>28.5&#8201;&#177;&#8201;0.88</td></tr><tr><td>MCV (fl)</td><td>86.7</td><td>85.5&#8201;&#177;&#8201;4.03</td><td>84.3&#8201;&#177;&#8201;2.69</td></tr><tr><td>MCHC (%)</td><td>31.4</td><td>32.7&#8201;&#177;&#8201;1.04</td><td>33.9&#8201;&#177;&#8201;0.64</td></tr><tr><td>Hb A<sub>2</sub> (%)</td><td>4.3</td><td>3.79&#8201;&#177;&#8201;0.24</td><td>3.92&#8201;&#177;&#8201;0.37</td></tr><tr><td>Hb F (%)</td><td>14.3</td><td>2.53&#8201;&#177;&#8201;1.8</td><td>1.60&#8201;&#177;&#8201;1.17</td></tr></tbody>
###xml 1296 1735 1276 1683 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="3">Hematological indices</th><th colspan="3"><italic>HBB</italic>:g.-101C&gt;T</th></tr><tr><th rowspan="2"><italic>HBG2</italic>:g.-109G&gt;T (I-3)</th><th>Wild-type</th><th>Wild-type</th></tr><tr><th>Females (<italic>n</italic>&#8201;=&#8201;18)</th><th>Males (<italic>n</italic>&#8201;=&#8201;13)</th></tr></thead><tbody><tr><td>Age (years)/sex</td><td>78/F</td><td>Adults</td><td>Adults</td></tr><tr><td>Hb (g/dL)</td><td>12.1</td><td>12.4&#8201;&#177;&#8201;1.22</td><td>14.5&#8201;&#177;&#8201;0.84</td></tr><tr><td>Hct (%)</td><td>38.5</td><td>37.1&#8201;&#177;&#8201;2.76</td><td>43.1&#8201;&#177;&#8201;2.30</td></tr><tr><td>RBC (&#215;10<sup>6</sup>)</td><td>4,440</td><td>4,382&#8201;&#177;&#8201;446</td><td>5,144&#8201;&#177;&#8201;265</td></tr><tr><td>MCH (pg)</td><td>27.3</td><td>28.4&#8201;&#177;&#8201;1.54</td><td>28.5&#8201;&#177;&#8201;0.88</td></tr><tr><td>MCV (fl)</td><td>86.7</td><td>85.5&#8201;&#177;&#8201;4.03</td><td>84.3&#8201;&#177;&#8201;2.69</td></tr><tr><td>MCHC (%)</td><td>31.4</td><td>32.7&#8201;&#177;&#8201;1.04</td><td>33.9&#8201;&#177;&#8201;0.64</td></tr><tr><td>Hb A<sub>2</sub> (%)</td><td>4.3</td><td>3.79&#8201;&#177;&#8201;0.24</td><td>3.92&#8201;&#177;&#8201;0.37</td></tr><tr><td>Hb F (%)</td><td>14.3</td><td>2.53&#8201;&#177;&#8201;1.8</td><td>1.60&#8201;&#177;&#8201;1.17</td></tr></tbody></table>
###xml 950 1735 936 1683 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="12">Comparison of the hematological indices, Hb A<sub>2</sub> and Hb F levels among the compound heterozygous for the novel <italic>HBG2</italic>:g.-109G&gt;T mutation and the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia mutation (I-3; see also Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a), and heterozygotes for the silent <italic>HBB</italic>:g.-101C&gt;T &#946;-thalassemia mutation (note the markedly increased Hb F levels in case I-3)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3">Hematological indices</th><th colspan="3"><italic>HBB</italic>:g.-101C&gt;T</th></tr><tr><th rowspan="2"><italic>HBG2</italic>:g.-109G&gt;T (I-3)</th><th>Wild-type</th><th>Wild-type</th></tr><tr><th>Females (<italic>n</italic>&#8201;=&#8201;18)</th><th>Males (<italic>n</italic>&#8201;=&#8201;13)</th></tr></thead><tbody><tr><td>Age (years)/sex</td><td>78/F</td><td>Adults</td><td>Adults</td></tr><tr><td>Hb (g/dL)</td><td>12.1</td><td>12.4&#8201;&#177;&#8201;1.22</td><td>14.5&#8201;&#177;&#8201;0.84</td></tr><tr><td>Hct (%)</td><td>38.5</td><td>37.1&#8201;&#177;&#8201;2.76</td><td>43.1&#8201;&#177;&#8201;2.30</td></tr><tr><td>RBC (&#215;10<sup>6</sup>)</td><td>4,440</td><td>4,382&#8201;&#177;&#8201;446</td><td>5,144&#8201;&#177;&#8201;265</td></tr><tr><td>MCH (pg)</td><td>27.3</td><td>28.4&#8201;&#177;&#8201;1.54</td><td>28.5&#8201;&#177;&#8201;0.88</td></tr><tr><td>MCV (fl)</td><td>86.7</td><td>85.5&#8201;&#177;&#8201;4.03</td><td>84.3&#8201;&#177;&#8201;2.69</td></tr><tr><td>MCHC (%)</td><td>31.4</td><td>32.7&#8201;&#177;&#8201;1.04</td><td>33.9&#8201;&#177;&#8201;0.64</td></tr><tr><td>Hb A<sub>2</sub> (%)</td><td>4.3</td><td>3.79&#8201;&#177;&#8201;0.24</td><td>3.92&#8201;&#177;&#8201;0.37</td></tr><tr><td>Hb F (%)</td><td>14.3</td><td>2.53&#8201;&#177;&#8201;1.8</td><td>1.60&#8201;&#177;&#8201;1.17</td></tr></tbody></table></table-wrap>
For the needs of this study, the mother and two sisters of the index case were also recruited. Unfortunately, the father of the index case was deceased, but, nevertheless, his sister was available for study (Fig. 1a). Also, 31 heterozygotes for the silent HBB:g.-101C>T beta-thalassemia mutation have been included (Table 1), as well as 89 normal (nonthalassemic) individuals. The study was previously approved by the hospital's ethics committee. Fig. 1a Family tree showing the heterozygous and compound heterozygous cases for the Hellenic type of nd-HPFH, bearing the novel HBG2:g.-109G>T promoter mutation (depicted in black) and the HBG2:g.-158C>T polymorphism (depicted in light gray) or the silent HBB:g.-101C>T beta-thalassemia nonsense mutation (depicted in dark gray), along with the corresponding hematological indices. b Chromatogram from RP-HPLC from the index case showing the significant increase in the Ggamma/Agamma-globin chain ratioTable 1Comparison of the hematological indices, Hb A2 and Hb F levels among the compound heterozygous for the novel HBG2:g.-109G>T mutation and the silent HBB:g.-101C>T beta-thalassemia mutation (I-3; see also Fig. 1a), and heterozygotes for the silent HBB:g.-101C>T beta-thalassemia mutation (note the markedly increased Hb F levels in case I-3)Hematological indicesHBB:g.-101C>THBG2:g.-109G>T (I-3)Wild-typeWild-typeFemales (n = 18)Males (n = 13)Age (years)/sex78/FAdultsAdultsHb (g/dL)12.112.4 +/- 1.2214.5 +/- 0.84Hct (%)38.537.1 +/- 2.7643.1 +/- 2.30RBC (x106)4,4404,382 +/- 4465,144 +/- 265MCH (pg)27.328.4 +/- 1.5428.5 +/- 0.88MCV (fl)86.785.5 +/- 4.0384.3 +/- 2.69MCHC (%)31.432.7 +/- 1.0433.9 +/- 0.64Hb A2 (%)4.33.79 +/- 0.243.92 +/- 0.37Hb F (%)14.32.53 +/- 1.81.60 +/- 1.17
###end p 10
###begin p 11
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 123 127 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 169 174 169 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">black</italic>
###xml 184 188 184 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 225 235 225 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">light gray</italic>
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 313 322 310 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">dark gray</italic>
###xml 377 378 374 375 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
a Family tree showing the heterozygous and compound heterozygous cases for the Hellenic type of nd-HPFH, bearing the novel HBG2:g.-109G>T promoter mutation (depicted in black) and the HBG2:g.-158C>T polymorphism (depicted in light gray) or the silent HBB:g.-101C>T beta-thalassemia nonsense mutation (depicted in dark gray), along with the corresponding hematological indices. b Chromatogram from RP-HPLC from the index case showing the significant increase in the Ggamma/Agamma-globin chain ratio
###end p 11
###begin p 12
###xml 45 46 45 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 148 151 148 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 208 209 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 246 249 243 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
Comparison of the hematological indices, Hb A2 and Hb F levels among the compound heterozygous for the novel HBG2:g.-109G>T mutation and the silent HBB:g.-101C>T beta-thalassemia mutation (I-3; see also Fig. 1a), and heterozygotes for the silent HBB:g.-101C>T beta-thalassemia mutation (note the markedly increased Hb F levels in case I-3)
###end p 12
###begin title 13
Hemoglobin studies
###end title 13
###begin p 14
###xml 189 190 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Blood samples were collected, with consent, in vacutainers with ethylenediaminetetraacetic acid as anticoagulant. Hematological indices were measured with an automated cell counter and Hb A2 and Hb F levels were quantitated, using cation exchange high-performance liquid chromatography (HPLC; VARIANTtrade mark, BioRad, Hercules, CA, USA). Globin chain quantitation was performed using reverse-phase HPLC, using the RP-18 column (Pharmacia, Uppsala, Sweden).
###end p 14
###begin title 15
DNA analysis
###end title 15
###begin p 16
###xml 109 110 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 380 381 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 384 387 376 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 392 395 384 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBD</italic>
###xml 469 471 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 502 504 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 632 638 624 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBA2/1</italic>
###xml 729 731 721 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 880 886 872 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBA2/1</italic>
###xml 965 967 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 139 144 <span type="species:ncbi:9606">human</span>
Total genomic DNA isolation and gamma-globin gene promoters' amplification was done as previously described [8]. Mutation screening in the human gamma-globin gene promoters was performed using denaturing gradient gel electrophoresis (DGGE) with a 40-70% linear gradient of denaturing agents (urea and formamide; 100% denaturant: 7 M urea, 40% formamide), as previously described [9]. HBB and HBD gene mutation screening was done as described in Losekoot and coworkers [10] and Papadakis and coworkers [11], respectively. Automated DNA sequencing was performed directly on the polymerase chain reaction (PCR) products. Screening for HBA2/1 gene deletions was done according to the multiplex gap-PCR strategy of Tan and coworkers [12], while a PCR-restriction fragment length polymorphism (RFLP) approach was used to screen for the commonest point mutations and small indels in the HBA2/1 genes, leading to nondeletional alpha-thalassemia in the Hellenic population [13].
###end p 16
###begin title 17
Electrophoretic mobility shift assays
###end title 17
###begin p 18
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 530 532 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 534 536 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
###xml 142 147 <span type="species:ncbi:9606">human</span>
Electrophoretic mobility shift assays (EMSA) analysis was performed using total nuclear protein extracts from mouse erythroleukemia (MEL) and human K562 cells [14]. In brief, 5 mug nuclear extracts were used per reaction and competitions were done using 100-fold molar excess of the indicated double-stranded oligonucleotides before addition of the nuclear extract. Nucleotide sequence of the oligonucleotides used in these studies is available upon request. Supershift analysis was performed using a home-brewed GATA-1 antibody [15, 16].
###end p 18
###begin title 19
Results
###end title 19
###begin p 20
###xml 205 206 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 294 298 283 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 331 332 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 367 371 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 523 527 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 544 545 533 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 735 739 720 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 765 769 750 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 900 906 885 891 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 906 907 891 892 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 952 956 937 941 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1013 1014 998 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1033 1037 1018 1022 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1048 1058 1033 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower band</italic>
###xml 1064 1068 1049 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1092 1102 1077 1087 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper band</italic>
###xml 1122 1132 1107 1117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes II-2</italic>
###xml 1137 1141 1122 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">II-3</italic>
###xml 1155 1164 1140 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes I-2</italic>
###xml 1169 1173 1154 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">II-1</italic>
###xml 1239 1242 1224 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 1247 1253 1232 1238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 1280 1281 1265 1266 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1420 1424 1405 1409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1440 1445 1425 1430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
###xml 906 1446 891 1431 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21"><bold>a</bold> DGGE analysis of the promoter region of the <italic>HBG2</italic> gene. Numbering correlates with the family tree in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a. Note the mutant <italic>HBG2</italic>:g.-158&#160;T (<italic>lower band</italic>) and <italic>HBG2</italic>:g.-109&#160;T homoduplexes (<italic>upper band</italic>) that comigrate in <italic>lanes II-2</italic> and <italic>II-3</italic>, compared to <italic>lanes I-2</italic> and <italic>II-1</italic>, respectively. The 40&#8211;70% denaturing gradient corresponds to the <italic>top</italic> and <italic>bottom</italic> of the gel, respectively. <bold>b</bold> DNA sequencing analysis, performed in the forward and reverse (not shown) orientation, revealing a G&gt;T transition at position &#8722;109 of the <italic>HBG2</italic> gene promoter (<italic>arrow</italic>)</p>
###xml 906 1446 891 1431 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21"><bold>a</bold> DGGE analysis of the promoter region of the <italic>HBG2</italic> gene. Numbering correlates with the family tree in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a. Note the mutant <italic>HBG2</italic>:g.-158&#160;T (<italic>lower band</italic>) and <italic>HBG2</italic>:g.-109&#160;T homoduplexes (<italic>upper band</italic>) that comigrate in <italic>lanes II-2</italic> and <italic>II-3</italic>, compared to <italic>lanes I-2</italic> and <italic>II-1</italic>, respectively. The 40&#8211;70% denaturing gradient corresponds to the <italic>top</italic> and <italic>bottom</italic> of the gel, respectively. <bold>b</bold> DNA sequencing analysis, performed in the forward and reverse (not shown) orientation, revealing a G&gt;T transition at position &#8722;109 of the <italic>HBG2</italic> gene promoter (<italic>arrow</italic>)</p></caption>
###xml 1446 1446 1431 1431 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="277_2008_643_Fig2_HTML" id="MO2"/>
###xml 900 1446 885 1431 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="21"><bold>a</bold> DGGE analysis of the promoter region of the <italic>HBG2</italic> gene. Numbering correlates with the family tree in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a. Note the mutant <italic>HBG2</italic>:g.-158&#160;T (<italic>lower band</italic>) and <italic>HBG2</italic>:g.-109&#160;T homoduplexes (<italic>upper band</italic>) that comigrate in <italic>lanes II-2</italic> and <italic>II-3</italic>, compared to <italic>lanes I-2</italic> and <italic>II-1</italic>, respectively. The 40&#8211;70% denaturing gradient corresponds to the <italic>top</italic> and <italic>bottom</italic> of the gel, respectively. <bold>b</bold> DNA sequencing analysis, performed in the forward and reverse (not shown) orientation, revealing a G&gt;T transition at position &#8722;109 of the <italic>HBG2</italic> gene promoter (<italic>arrow</italic>)</p></caption><graphic position="anchor" xlink:href="277_2008_643_Fig2_HTML" id="MO2"/></fig>
During routine carrier screening for beta-thalassemia, an adult female subject was identified with moderately elevated Hb F levels (4.1%) and significantly increased Ggamma/Agamma-globin chain ratio (Fig. 1b). An aberrant electrophoretic pattern was identified during mutation screening in the HBG2 promoter by DGGE analysis (Fig. 2a). DNA sequencing of the proximal HBG2 promoter region revealed a novel sequence variation, namely, a G>T transversion at position -109 relative to the gene's transcription initiation site (HBG2:g.-109G>T; Fig. 2b). DNA sequencing did not reveal any other variant nucleotide in either one of the gamma-globin genes promoters and distal 5' regulatory regions between positions -672 and +25. Neither the HBG2:g.-158C>T (XmnI) nor the HBG1:g.-225-222(AGCA)del polymorphisms, which are often correlated with moderately increased HbF levels, were found in the index case. Fig. 2a DGGE analysis of the promoter region of the HBG2 gene. Numbering correlates with the family tree in Fig. 1a. Note the mutant HBG2:g.-158 T (lower band) and HBG2:g.-109 T homoduplexes (upper band) that comigrate in lanes II-2 and II-3, compared to lanes I-2 and II-1, respectively. The 40-70% denaturing gradient corresponds to the top and bottom of the gel, respectively. b DNA sequencing analysis, performed in the forward and reverse (not shown) orientation, revealing a G>T transition at position -109 of the HBG2 gene promoter (arrow)
###end p 20
###begin p 21
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 127 131 127 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 142 152 142 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower band</italic>
###xml 158 162 158 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 186 196 186 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">upper band</italic>
###xml 216 226 216 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes II-2</italic>
###xml 231 235 231 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">II-3</italic>
###xml 249 258 249 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lanes I-2</italic>
###xml 263 267 263 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">II-1</italic>
###xml 333 336 333 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">top</italic>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bottom</italic>
###xml 374 375 374 375 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 514 518 514 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 534 539 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink">arrow</italic>
a DGGE analysis of the promoter region of the HBG2 gene. Numbering correlates with the family tree in Fig. 1a. Note the mutant HBG2:g.-158 T (lower band) and HBG2:g.-109 T homoduplexes (upper band) that comigrate in lanes II-2 and II-3, compared to lanes I-2 and II-1, respectively. The 40-70% denaturing gradient corresponds to the top and bottom of the gel, respectively. b DNA sequencing analysis, performed in the forward and reverse (not shown) orientation, revealing a G>T transition at position -109 of the HBG2 gene promoter (arrow)
###end p 21
###begin p 22
###xml 132 136 132 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 236 240 236 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 514 515 514 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 619 623 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 667 670 667 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 712 716 709 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 823 826 817 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 920 924 914 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1003 1006 997 1000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBD</italic>
###xml 1075 1077 1069 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1103 1106 1097 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBD</italic>
###xml 1201 1207 1195 1201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBA2/1</italic>
###xml 1280 1286 1274 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBA2/1</italic>
Hemoglobin studies and DNA analysis of the available family members indicated that the propositus mother (I-2) was a carrier of the HBG2:g.-158C>T (XmnI) polymorphism, while both sisters (II-2, II-3) were compound heterozygotes for the HBG2:g.-158C>T polymorphism and the novel HBG2:g.-109G>T mutation. Surprisingly, in the latter cases, Hb F levels were normal. Although the propositus father was deceased, his sister, who was available for study, presented with significantly increased Hb F levels (14.3%; Table 1, Fig. 1a). DNA analysis revealed that the propositus aunt (I-3) was also compound heterozygous for the HBG2:g.-109G>T promoter mutation and the silent HBB:g.-101C>T beta-thalassemia mutation. The HBG2:g.-109G>T base substitution was neither identified in 31 beta-thalassemic chromosomes, bearing the silent HBB:g.-101C>T mutation nor in 209 normal (nonthalassemic) chromosomes, suggesting that the novel HBG2:g.-109G>T variation is not a frequent polymorphism. Mutation screening in the HBD gene in the index case and her family members, using DGGE analysis [11], failed to identify any HBD mutations (data not shown). In addition, all family members were not carriers either of known HBA2/1 gene deletions or the commonest point mutations and small indels in the HBA2/1 genes, determined by gap-PCR and PCR-RFLP analysis, respectively.
###end p 22
###begin p 23
###xml 60 64 60 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 314 317 298 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 377 379 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 576 580 560 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 733 737 717 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 941 945 925 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 950 953 934 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 965 967 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 1085 1086 1069 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 1369 1373 1353 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1608 1612 1592 1596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1637 1641 1621 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1751 1753 1735 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1784 1788 1768 1772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1860 1866 1844 1850 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 1866 1867 1850 1851 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1963 1965 1947 1949 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wt</italic>
###xml 1967 1971 1951 1955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1992 1994 1976 1978 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mt</italic>
###xml 1996 2000 1980 1984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 2106 2110 2090 2094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 2199 2212 2183 2196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">two asterisks</italic>
###xml 2243 2247 2227 2231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 2375 2379 2359 2363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 2432 2436 2416 2420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 2445 2448 2429 2432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 2474 2476 2458 2460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 2527 2532 2511 2516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower</italic>
###xml 2568 2572 2552 2556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 2581 2584 2565 2568 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 2813 2821 2797 2805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisk</italic>
###xml 2876 2879 2860 2863 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 2902 2903 2886 2887 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 2987 2991 2971 2975 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 2996 2999 2980 2983 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 3005 3009 2989 2993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 3014 3018 2998 3002 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 3034 3044 3018 3028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined</italic>
###xml 3180 3183 3164 3167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 3185 3193 3169 3177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gray box</italic>
###xml 3284 3301 3268 3285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">solid black boxes</italic>
###xml 3358 3361 3342 3345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1866 3381 1850 3365 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="24"><bold>a</bold> Electrophoretic mobility shift assays of the oligonucleotides containing either the wild-type (<italic>Wt</italic>; <italic>HBG2</italic>:g-109&#160;G) or mutant (<italic>Mt</italic>; <italic>HBG2</italic>:g-109&#160;T) sequence using nuclear protein extracts prepared from dimethyl sulfoxide-induced MEL cells. The <italic>HBG2</italic> &#8722;109Mt oligonucleotide most likely abolishes a NF-E3 binding site in vitro (depicted as <italic>two asterisks</italic>). Competition with nonlabeled <italic>HBG2</italic> &#8722;109Wt oligonucleotide results in the disappearance of GATA-1 and NF-E3 band shifts, suggesting that both proteins bind to the <italic>HBG2</italic> &#8722;109Wt oligonucleotide. Competition with nonlabeled <italic>HBG2</italic> &#8722;567 or <italic>HBB</italic> GATA-1 oligonucleotides [<xref ref-type="bibr" rid="CR15">15</xref>] results in the disappearance only of the GATA-1 (<italic>lower</italic>) band. Competition with nonlabeled <italic>HBG2</italic> &#8722;567 or <italic>HBB</italic> GATA-1 oligonucleotides suggests that the affinity of GATA-1 is stronger to the former oligonucleotide. Use of nuclear protein extracts prepared from K562 cells yielded identical electrophoretic mobility shifts (not shown). The <italic>asterisk</italic> indicates the oligonucleotide sequence located in the <italic>HBB</italic> gene promoter region. <bold>b</bold> Schematic representation of the various nd-HPFH mutations reported to date for the <italic>HBG2</italic> (in <italic>red</italic>) and <italic>HBG1</italic> (in <italic>blue</italic>) globin genes (<italic>underlined</italic> sequences depict the two small deletions also leading to nd-HPFH). The novel nd-HPFH mutation reported in this study is highlighted in <italic>red</italic>. <italic>Gray box</italic> represents the sequences downstream to the transcription initiation site and sequences in <italic>solid black boxes</italic> represent phylogenetically conserved fetal globin genes <italic>cis</italic>-regulatory elements</p>
###xml 1866 3381 1850 3365 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="24"><bold>a</bold> Electrophoretic mobility shift assays of the oligonucleotides containing either the wild-type (<italic>Wt</italic>; <italic>HBG2</italic>:g-109&#160;G) or mutant (<italic>Mt</italic>; <italic>HBG2</italic>:g-109&#160;T) sequence using nuclear protein extracts prepared from dimethyl sulfoxide-induced MEL cells. The <italic>HBG2</italic> &#8722;109Mt oligonucleotide most likely abolishes a NF-E3 binding site in vitro (depicted as <italic>two asterisks</italic>). Competition with nonlabeled <italic>HBG2</italic> &#8722;109Wt oligonucleotide results in the disappearance of GATA-1 and NF-E3 band shifts, suggesting that both proteins bind to the <italic>HBG2</italic> &#8722;109Wt oligonucleotide. Competition with nonlabeled <italic>HBG2</italic> &#8722;567 or <italic>HBB</italic> GATA-1 oligonucleotides [<xref ref-type="bibr" rid="CR15">15</xref>] results in the disappearance only of the GATA-1 (<italic>lower</italic>) band. Competition with nonlabeled <italic>HBG2</italic> &#8722;567 or <italic>HBB</italic> GATA-1 oligonucleotides suggests that the affinity of GATA-1 is stronger to the former oligonucleotide. Use of nuclear protein extracts prepared from K562 cells yielded identical electrophoretic mobility shifts (not shown). The <italic>asterisk</italic> indicates the oligonucleotide sequence located in the <italic>HBB</italic> gene promoter region. <bold>b</bold> Schematic representation of the various nd-HPFH mutations reported to date for the <italic>HBG2</italic> (in <italic>red</italic>) and <italic>HBG1</italic> (in <italic>blue</italic>) globin genes (<italic>underlined</italic> sequences depict the two small deletions also leading to nd-HPFH). The novel nd-HPFH mutation reported in this study is highlighted in <italic>red</italic>. <italic>Gray box</italic> represents the sequences downstream to the transcription initiation site and sequences in <italic>solid black boxes</italic> represent phylogenetically conserved fetal globin genes <italic>cis</italic>-regulatory elements</p></caption>
###xml 3381 3381 3365 3365 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="277_2008_643_Fig3_HTML" id="MO3"/>
###xml 1860 3381 1844 3365 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="24"><bold>a</bold> Electrophoretic mobility shift assays of the oligonucleotides containing either the wild-type (<italic>Wt</italic>; <italic>HBG2</italic>:g-109&#160;G) or mutant (<italic>Mt</italic>; <italic>HBG2</italic>:g-109&#160;T) sequence using nuclear protein extracts prepared from dimethyl sulfoxide-induced MEL cells. The <italic>HBG2</italic> &#8722;109Mt oligonucleotide most likely abolishes a NF-E3 binding site in vitro (depicted as <italic>two asterisks</italic>). Competition with nonlabeled <italic>HBG2</italic> &#8722;109Wt oligonucleotide results in the disappearance of GATA-1 and NF-E3 band shifts, suggesting that both proteins bind to the <italic>HBG2</italic> &#8722;109Wt oligonucleotide. Competition with nonlabeled <italic>HBG2</italic> &#8722;567 or <italic>HBB</italic> GATA-1 oligonucleotides [<xref ref-type="bibr" rid="CR15">15</xref>] results in the disappearance only of the GATA-1 (<italic>lower</italic>) band. Competition with nonlabeled <italic>HBG2</italic> &#8722;567 or <italic>HBB</italic> GATA-1 oligonucleotides suggests that the affinity of GATA-1 is stronger to the former oligonucleotide. Use of nuclear protein extracts prepared from K562 cells yielded identical electrophoretic mobility shifts (not shown). The <italic>asterisk</italic> indicates the oligonucleotide sequence located in the <italic>HBB</italic> gene promoter region. <bold>b</bold> Schematic representation of the various nd-HPFH mutations reported to date for the <italic>HBG2</italic> (in <italic>red</italic>) and <italic>HBG1</italic> (in <italic>blue</italic>) globin genes (<italic>underlined</italic> sequences depict the two small deletions also leading to nd-HPFH). The novel nd-HPFH mutation reported in this study is highlighted in <italic>red</italic>. <italic>Gray box</italic> represents the sequences downstream to the transcription initiation site and sequences in <italic>solid black boxes</italic> represent phylogenetically conserved fetal globin genes <italic>cis</italic>-regulatory elements</p></caption><graphic position="anchor" xlink:href="277_2008_643_Fig3_HTML" id="MO3"/></fig>
###xml 463 468 <span type="species:ncbi:9606">human</span>
In order to verify the functional significance of the novel HBG2:g.-109G>T mutation, we measured Ggamma-globin chain levels, using reverse-phase HPLC. Our results showed that the Ggamma/Alphagamma-globin chain ratio was significantly increased, compared to normal (nonthalassemic) individuals and carriers for the HBB:g.-101C>T mutation (79.2/20.8 versus 40/60, respectively) [17]. Also, we performed EMSA analysis, using nuclear extracts from both MEL cells and human K562 cells, expressing the adult and fetal erythroid program, respectively, in order to assess whether the HBG2:g.-109G>T mutation affects protein binding in vitro. Indeed, EMSA analysis using a 40-bp oligonucleotide bearing the wild-type sequence (G) at position HBG2:g.-109 showed a double-band electrophoretic pattern, suggesting that two proteins and/or protein complexes bind to the oligonucleotide used. Addition of nonradioactive GATA-1 oligonucleotides, both from HBG2 and HBB promoters [15], resulted only in the lower band being efficiently competed, contrary to the upper band that remained visible (Fig. 3a), indicating that the lower band most likely represents GATA-1 binding. This finding was confirmed using GATA-1 antibody, resulting in a supershift of the lower (GATA-1) band (data not shown). EMSA analysis using a 40-bp oligonucleotide bearing the mutant sequence (T) at position HBG2:g.-109 revealed that binding of the protein (or protein complex) in the upper band was abolished. These data indicate that the upper band shift represent protein (or protein complex) binding only to the wild-type sequence at position HBG2:g.-109 (G) and that the HBG2:g.-109G>T transversion inhibits protein binding in vitro. Consistent with previous footprinting experiments [18], these data suggest that the HBG2:g.-109G>T mutation is responsible for the resulting nd-HPFH phenotype. Fig. 3a Electrophoretic mobility shift assays of the oligonucleotides containing either the wild-type (Wt; HBG2:g-109 G) or mutant (Mt; HBG2:g-109 T) sequence using nuclear protein extracts prepared from dimethyl sulfoxide-induced MEL cells. The HBG2 -109Mt oligonucleotide most likely abolishes a NF-E3 binding site in vitro (depicted as two asterisks). Competition with nonlabeled HBG2 -109Wt oligonucleotide results in the disappearance of GATA-1 and NF-E3 band shifts, suggesting that both proteins bind to the HBG2 -109Wt oligonucleotide. Competition with nonlabeled HBG2 -567 or HBB GATA-1 oligonucleotides [15] results in the disappearance only of the GATA-1 (lower) band. Competition with nonlabeled HBG2 -567 or HBB GATA-1 oligonucleotides suggests that the affinity of GATA-1 is stronger to the former oligonucleotide. Use of nuclear protein extracts prepared from K562 cells yielded identical electrophoretic mobility shifts (not shown). The asterisk indicates the oligonucleotide sequence located in the HBB gene promoter region. b Schematic representation of the various nd-HPFH mutations reported to date for the HBG2 (in red) and HBG1 (in blue) globin genes (underlined sequences depict the two small deletions also leading to nd-HPFH). The novel nd-HPFH mutation reported in this study is highlighted in red. Gray box represents the sequences downstream to the transcription initiation site and sequences in solid black boxes represent phylogenetically conserved fetal globin genes cis-regulatory elements
###end p 23
###begin p 24
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 97 99 97 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wt</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 126 128 126 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mt</italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 333 346 333 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">two asterisks</italic>
###xml 377 381 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 509 513 509 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 566 570 566 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 579 582 579 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 661 666 661 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">lower</italic>
###xml 702 706 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 715 718 715 718 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 947 955 947 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink">asterisk</italic>
###xml 1010 1013 1010 1013 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 1036 1037 1036 1037 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1121 1125 1121 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1130 1133 1130 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1139 1143 1139 1143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 1148 1152 1148 1152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue</italic>
###xml 1168 1178 1168 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">underlined</italic>
###xml 1314 1317 1314 1317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 1319 1327 1319 1327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gray box</italic>
###xml 1418 1435 1418 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">solid black boxes</italic>
###xml 1492 1495 1492 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
a Electrophoretic mobility shift assays of the oligonucleotides containing either the wild-type (Wt; HBG2:g-109 G) or mutant (Mt; HBG2:g-109 T) sequence using nuclear protein extracts prepared from dimethyl sulfoxide-induced MEL cells. The HBG2 -109Mt oligonucleotide most likely abolishes a NF-E3 binding site in vitro (depicted as two asterisks). Competition with nonlabeled HBG2 -109Wt oligonucleotide results in the disappearance of GATA-1 and NF-E3 band shifts, suggesting that both proteins bind to the HBG2 -109Wt oligonucleotide. Competition with nonlabeled HBG2 -567 or HBB GATA-1 oligonucleotides [15] results in the disappearance only of the GATA-1 (lower) band. Competition with nonlabeled HBG2 -567 or HBB GATA-1 oligonucleotides suggests that the affinity of GATA-1 is stronger to the former oligonucleotide. Use of nuclear protein extracts prepared from K562 cells yielded identical electrophoretic mobility shifts (not shown). The asterisk indicates the oligonucleotide sequence located in the HBB gene promoter region. b Schematic representation of the various nd-HPFH mutations reported to date for the HBG2 (in red) and HBG1 (in blue) globin genes (underlined sequences depict the two small deletions also leading to nd-HPFH). The novel nd-HPFH mutation reported in this study is highlighted in red. Gray box represents the sequences downstream to the transcription initiation site and sequences in solid black boxes represent phylogenetically conserved fetal globin genes cis-regulatory elements
###end p 24
###begin title 25
Discussion
###end title 25
###begin p 26
###xml 125 129 125 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 220 221 220 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 300 304 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 316 317 316 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 370 374 370 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
In this paper, we report the Hellenic type of nd-HPFH, resulting from a novel G>T transversion in the promoter region of the HBG2 gene. In the Hellenic population, the dominant nd-HPFH is the Greek type (HBG1:g.-117G>A [6]), accounting for almost 90% of the HPFH chromosomes [9]. The Cretan nd-HPFH (HBG1:g.-158C>T [9]) is the second most frequent type, followed by the HBG1:g.-201C>T and the HBG2:g.-196C>T mutations [19]. No deletional HPFH has even been reported for the Hellenic population.
###end p 26
###begin p 27
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 158 161 158 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 239 242 236 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 308 310 302 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 312 314 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 425 429 419 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 566 569 560 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
###xml 741 743 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 906 908 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 910 912 895 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 964 968 949 953 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 996 1000 981 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1072 1073 1057 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 1143 1147 1128 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1211 1215 1196 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1267 1270 1252 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 1404 1406 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
The HBG2:g.-109G>T mutation was found both in heterozygosity as well as in compound heterozygosity with the HBG2:g.-158C>T (XmnI) polymorphism and the silent HBB:g.-101C>T beta-thalassemia mutation, the latter being one of the most common HBB mutation leading to beta-thalassemia in the Hellenic population [20, 21]. Interestingly, however, the resulting Hb F levels varied in each case. First of all, heterozygosity for the HBG2:g.-109G>T mutation resulted in moderately increased Hb F levels in the index case (4.1%). Also, compound heterozygosity with the silent HBB:g.-101C>T beta-thalassemia mutation resulted in substantially increased Hb F levels (14.3%), as expected for compound heterozygous cases for nd-HPFH and beta-thalassemia [22]. There are very few examples of nd-HPFH/beta-thalassemia compound heterozygous cases, which are extremely rare and only occasionally reported in the literature [22, 23]. On the contrary, compound heterozygosity for the HBG2:g.-109G>T mutation and the HBG2:g.-158C>T polymorphism has no effect in the observed Hb F levels (Fig. 1a). There are two possible explanations for this observation: (a) the HBG2:g.-158C>T polymorphism itself exerts a silencing effect on the HBG2:g.-109G>T mutation or (b) another yet unidentified cis-regulatory element suppresses Hb F production in the sisters of the index case. The latter assumption resembles our recent findings [16] and reaffirms that the regulation of gamma-globin gene expression and Hb F production is multifactorial and likely combinatorial and that many genetic factors can putatively impact Hb F production in adults.
###end p 27
###begin p 28
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 322 324 318 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 326 328 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 368 372 364 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 446 448 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 471 475 467 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 647 651 643 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 728 729 724 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 837 838 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 879 883 871 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
The HBG2:g.-109G>T mutation resides at the 3' end of the distal HBG2 CCAAT box where the CP1 and NF-E3 transcription factors bind [18]. On the basis of in vitro binding studies, GATA-1 and NF-E3 have both been implicated as candidate suppressors of gamma-globin gene transcription that would act by binding to the region [18, 24]. In particular, guanosine at position HBG2:g.-109 has been previously shown to be a strong contact point for NF-E3 [24], suggesting that the HBG2:g.-109G>T transversion activates Hb F production most likely by abolishing NF-E3 binding. This assumption is in accordance with our EMSA analysis data indicating that the HBG2:g.-109G>T transversion results in abolishing protein binding in vitro (Fig. 3a). Taking into consideration that the Ggamma-globin chain levels were doubled in the index case (I-1; Fig. 1a), these data strongly suggest that the HBG2:g.-109G>T mutation is responsible for the resulting HPFH phenotype.
###end p 28
###begin p 29
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 142 145 142 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">cis</italic>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 560 564 556 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 677 681 673 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 780 782 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 814 818 810 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 1099 1101 1091 1093 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1208 1212 1196 1200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 1227 1231 1215 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 1400 1402 1388 1390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1499 1514 <span type="species:ncbi:10090">transgenic mice</span>
The novel nd-HPFH mutation described in this paper is located at the 3' end of the HBG2 gene's distal CCAAT box, a phylogenetically conserved cis-regulatory element that has been shown to harbor many ubiquitous and erythroid-specific transcription factor binding sites [1]. Nine out of 21 nd-HPFH mutations have been identified in this region (Fig. 3b), suggesting that this regulatory element is critical for gamma-globin gene transcription. Contrary, however, to the majority of these nd-HPFH mutations that have a substantial effect in Hb F production, the HBG2:g.-109G>T nd-HPFH mutation per se results in only moderate increase in HbF levels. In addition, the neighboring HBG2:g.-110A>C mutation, leading to the Czech nd-HPFH, also has a negligible effect in HbF production [25]. This is unexpected since the HBG1:g.-117G>A nd-HPFH mutation, residing at the 5' end of the distal CCAAT box, leads to a substantial increase in gamma-globin gene transcription. This can be explained by the fact that (a) different mutations in the distal CCAAT box abolish different transcription factors binding [24], which would exert a differential effect over gamma-globin gene reactivation in the adult stage, (b) the HBG1:g.-117G>A and HBG2:g.-109G>T reside on different genes, hence their relative distance from the LCR, being directly proportional to the frequency of LCR/globin gene promoter interactions [26], varies. It is noteworthy that not all nd-HPFH mutations give a reproducible HPFH phenotype in transgenic mice (unpublished data).
###end p 29
###begin p 30
###xml 197 201 193 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG1</italic>
###xml 202 206 198 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBG2</italic>
###xml 211 214 207 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HBB</italic>
Altogether, these data emphasize that gamma-globin gene silencing should be the result of a gradual change in the transcription factor environment affecting the transcriptional balance between the HBG1/HBG2 and HBB genes.
###end p 30
###begin title 31
Acknowledgements
###end title 31
###begin p 32
This work was partly supported by grants from the Greek Ministry of Education (Pythagoras 52211.08) to PK and the Research Promotion Foundation (Cyprus, PiDeltaEpsilon046_02) and the European Commission [International Thalassemia Network (ITHANET) Coordination action 026539] to GPP.
###end p 32
###begin title 33
References
###end title 33
###begin article-title 34
Hemoglobin switching
###end article-title 34
###begin article-title 35
Transcription complex stability and chromatin dynamics in vivo
###end article-title 35
###begin article-title 36
Deltabeta thalassemia and hereditary persistence of fetal hemoglobin
###end article-title 36
###begin article-title 37
Fetal gene reactivation
###end article-title 37
###begin article-title 38
###xml 32 37 <span type="species:ncbi:9606">human</span>
HbVar: a relational database of human hemoglobin variants and thalassemia mutations at the globin gene server
###end article-title 38
###begin article-title 39
G to A substitution in the distal CCAAT box of the A gamma-globin gene in Greek hereditary persistence of fetal haemoglobin
###end article-title 39
###begin article-title 40
A single point mutation is the cause of the Greek form of hereditary persistence of fetal haemoglobin
###end article-title 40
###begin article-title 41
A novel DNA polymorphism of the Agamma globin gene (Agamma-588 A>G) is linked with the XmnI polymorphism (Ggamma-158 C>T)
###end article-title 41
###begin article-title 42
The Cretan type of non-deletional hereditary persistence of fetal hemoglobin [Agamma-158 C>T] results from two independent gene conversion events
###end article-title 42
###begin article-title 43
Denaturing gradient gel electrophoresis and direct sequencing of PCR amplified genomic DNA: a rapid and reliable diagnostic approach to beta thalassemia
###end article-title 43
###begin article-title 44
Scanning method to identify the molecular heterogeneity of the delta-globin gene, especially in delta-thalassemias: detection of three novel mutations in the promoter region of the gene
###end article-title 44
###begin article-title 45
A rapid and reliable 7-deletion multiplex polymerase chain reaction assay for alpha-thalassemia
###end article-title 45
###begin article-title 46
Hellenic National Mutation database: a prototype database for mutations leading to inherited disorders in the Hellenic population
###end article-title 46
###begin article-title 47
###xml 70 78 <span type="species:ncbi:9606">patients</span>
Increased gamma-globin gene expression in beta-thalassemia intermedia patients correlates with a mutation in 3'HS1
###end article-title 47
###begin article-title 48
A novel single nucleotide polymorphism (SNP), T>G, in the GATA site at nucleotide (nt) -567 5' to the Ggamma-globin gene may be associated with elevated Hb F
###end article-title 48
###begin article-title 49
A T-to-G transversion at nucleotide -567 upstream of HBG2 in a GATA-1 binding motif is associated with elevated hemoglobin F
###end article-title 49
###begin article-title 50
###xml 65 72 <span type="species:ncbi:9606">infants</span>
The chemical heterogeneity of fetal hemoglobin in normal newborn infants and in adults
###end article-title 50
###begin article-title 51
###xml 74 79 <span type="species:ncbi:9606">human</span>
Differential binding of the NFE3 and CP1/NFY transcription factors to the human gamma- and epsilon-globin CCAAT boxes
###end article-title 51
###begin article-title 52
(G)gamma-196 C->T, (A)gamma-201 C->T: two novel mutations in the promoter region of the gamma-globin genes associated with nondeletional hereditary persistence of fetal hemoglobin in Greece
###end article-title 52
###begin article-title 53
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HbVar</italic>
###xml 26 31 <span type="species:ncbi:9606">human</span>
Improvements in the HbVar human hemoglobin variants and thalassemia mutations for population and sequence variation studies
###end article-title 53
###begin article-title 54
FINDbase: a relational database recording frequencies of genetic defects leading to inherited disorders worldwide
###end article-title 54
###begin article-title 55
A comparative study of Greek non-deletional hereditary persistence of fetal hemoglobin and beta-thalassemia compound heterozygotes
###end article-title 55
###begin article-title 56
Compound heterozygosity for the Cretan type of non-deletional hereditary persistence of fetal hemoglobin and beta-thalassemia or Hb Sabine confirms the functional role of the Agamma-158 C>T mutation in gamma-globin gene transcription
###end article-title 56
###begin article-title 57
Role of the duplicated CCAAT box region in gamma-globin gene regulation and hereditary persistence of fetal haemoglobin
###end article-title 57
###begin article-title 58
Compound heterozygosity for a beta0-thalassemia (frameshift codons 38/39; -C) and a nondeletional Swiss type of HPFH (A>C) at NT -110, Ggamma) in a Czechoslovakian family
###end article-title 58
###begin article-title 59
Multiple interactions between regulatory regions are required to stabilize an active chromatin hub
###end article-title 59
###begin p 60
Marios Phylactides and Farzin Pourfarzad contributed equally to this work.
###end p 60

